Slide 1: Insulet Corporation Q3 2023 Earnings
Insulet Corporation Q3 2023 Earnings November 2, 2023 Christian D Podder Since 2020
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements regarding, among other things, future operating and financial performance, product success and efficacy, the outcome of studies and trials and the approval of products by regulatory bodies. These forward-looking statemen
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures The Company uses the following non-GAAP financial measures: • Constant currency revenue growth represents the change in revenue between current and prior year periods using the exchange rate in effect during the applicable prior year period. Insulet presents constant curr
Slide 4: Recent Highlights
Recent Highlights Highlights • Commercially launched Omnipod 5 in Germany • Launched commercial pilot program for Omnipod GO • Received FDA 510(k) clearance for Omnipod 5 iOS app • Omnipod 5 pivotal extension data published in Diabetes Technology and Therapeutics demonstrating safety and improved ou
Slide 5: Strategic Highlights
Strategic Highlights Grant H Morgan M Alecia B Podder Since 2022 Podder Since 2009 Podder Since 2017 Expand Access & Awareness International Innovation & Clinical • Omnipod 5 represented vast majority of • Building cloud-based infrastructure to • Received FDA 510(k) clearance for Omnipod U.S. new cu
Slide 6: Financial Performance
Financial Performance Total Revenue & Growth Rates1 U.S. Omnipod Revenue and Growth Rates1 Adjusted Gross Profit and Margin2 Int'l Omnipod Revenue and Growth Rates1 Adjusted Operating Income & Margin2 Total Omnipod Revenue & Growth Rates1 1. Growth rates are on a year-over-year basis and for 2020 th
Slide 7: Key Commercial Metrics- Q3 2023
Key Commercial Metrics- Q3 2023 ~80% ~20% 90% - 95% of U.S. New of U.S. New of U.S. Volume Starts were MDI Starts were through Type 2 Pharmacy Vast ~90% Stable Majority Global Global of U.S. New Retention Utilization Starts on Omnipod 5 Note: All commercial metrics are directional estimates derived
Slide 8: Product Development Status- Q3 2023
Product Development Status- Q3 2023 Legend Innovation Pipeline U.S. Commercialized Regulatory Product International Submission Development Classic Omnipod Omnipod DASH Omnipod 5 U.S. full market release August 2022 CE Mark September 2022; w/ G6 UK release in June 2023 On track for additional int'l l
Slide 9: Guidance Highlights - 2023
Guidance Highlights - 2023 FY 2023 Q4 2023 FY 2023 Adjusted FY 2023 Adjusted Revenue Growth1 Revenue Growth1 Gross Margin2 Operating Margin2 26% to 27% 22% to 25% 66% to 67% 9% to 10% (expect mid- (closer to the high point) end) U.S. Omnipod U.S. Omnipod 37% to 38% 28% to 31% International Omnipod I
Slide 10: Revenue Guidance Reconciliation
Revenue Guidance Reconciliation FY 2023 Q4 2023 Revenue Growth Currency Revenue Growth Currency GAAP Impact Constant Currency GAAP Impact Constant Currency U.S. Omnipod 37% to 38% —% 37% to 38% 28% to 31% —% 28% to 31% International Omnipod 10% to 11% 1% 9% to 10% 8% to 11% 3% 5% to 8% Total Omnipod
Slide 11: Reconciliation of Non-GAAP Measures
Reconciliation of Non-GAAP Measures % of % of % of % of % of FY2020 Revenue FY2021 Revenue FY2022 Revenue Q3'2022 Revenue Q3'2023 Revenue Total Revenue GAAP Growth Rate 22.5% 21.5% 18.8% 23.7% 27.0% Less: Currency Impact 0.6% 1.8% (3.7)% (4.8)% 1.9% Constant Currency 21.9% 19.7% 22.5% 28.5% 25.1% To